Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Angle, Millennium Health, Exosome Diagnostics, and More

NEW YORK (360Dx) – Liquid biopsy company Angle this week reported interim financial results for the six months ended Oct. 31, 2017. The firm's revenues for H2 2017 were £200,000 ($283,286), equivalent to its revenues in H1 2017. Angle also reported a loss from continuing operations of £3.4 million and a cash balance of £4.3 million as of Oct. 31. The firm further said it now has an installed base of more than 145 Parsortix instruments deployed worldwide, up from 120 installed instruments in H1 2017, and completed more than 39,000 blood separations in the second half of the year.

Millennium Health said this week that it has received credentials to operate as a laboratory under the Medi-Cal program. Physicians can now order Millennium's clinical services for the 2.5 million fee-for-service members in California's Medicaid program, including its Millennium UDT for urine drug testing, its Millennium OFT for oral fluid testing, and DxWound, a DNA test offered by Millennium brand CogenDx.  The company said last week it received CAP accreditation for DxWound.

Exosome Diagnostics this week executed an agreement to provide its ExoDx Prostate test through FedMed, a PPO with 40 million members in the US. ExoDx is a prostate cancer risk assessment test and is now available to FedMed's members as a covered benefit through its payor network.

Medidata and Syapse said this week that they are collaborating to jointly develop products to improve patient access to oncology clinical trials. Under the terms of the agreement, the companies will initially build products to assist trial sponsors in designing eligibility criteria, identify community health systems as trial sites, and enable oncologists to easily identify patients for enrollment into trials.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.